NextCell is attending a conference for worldleading celltherapies

NextCell Pharma AB ("NextCell" or the"Company") is attending the International Society for Cell and Gene Therapy 2022 in San Francisco, May 4-7. The company is represented by Mathias Svahn, CEO who is a member of the Business Development and Finance Committee will participate in workshops, round table discussions and partnering meetings.

Established in 1992, ISCT is the global society fostering cell and gene therapy translation to the clinic. The society is comprised of over 2,200 cell therapy experts across five geographic regions and from over 60 countries. ISCT members are part of a global community of peers, thought leaders and organizations invested in cell therapy translation.ISCT leads the field in the translational aspects of developing cell and genebased therapeutics, advancing scientific research into innovative treatments for patients. ISCT has built a unique collaborative environment that advances three key areas of clinical translation: Academia, Regulatory and Commercialization. This has been achieved through long-term strategic relationships with global regulatory agencies, academic institutions, and industry partners internationally.

‍

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: 08-735 5595
E-mail: info@nextcellpharma.com
Websites:www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk
‍

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Instagram: https://www.instagram.com/cellaviva/

‍

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO)